Komatsu Ryu, Nash Michael, Peperzak Katherin A, Ziga Taylor M, Dinges Emily M, Delgado Carlos, Wu Jiang, Terman Gregory W, Dale Rebecca C
Departments of Anesthesiology and Pain Medicine.
Statistics, University of Washington, Seattle, WA.
Clin J Pain. 2022 Feb 8;38(5):311-319. doi: 10.1097/AJP.0000000000001019.
Buprenorphine is a partial agonist at mu-opioid receptors and competes for these receptors with other opioids in vitro. Whether patients on buprenorphine maintenance require high doses of opioid analgesics to attain adequate postoperative pain control has not been determined. We evaluated differences in acute postoperative opioid consumption and pain burden between patients taking buprenorphine and those taking methadone preoperatively.
A retrospective review of medical records of 928 patients, of whom 195 were on buprenorphine and 733 were on methadone preoperatively, was performed. Among methadone and buprenorphine patients, 615 and 89, respectively, continued to receive the medications postoperatively. Buprenorphine patients were compared with methadone patients for the first 48 hours postoperatively with regard to acute opioid dose requirements (morphine milligram equivalents [MME] above their baseline buprenorphine and methadone doses) and time-weighted average (TWA) pain scores (using targeted maximum likelihood estimation).
Opioid dose requirements for 48 hours postoperatively were 150 (22 to 297) (median [interquartile range]) and 220 [90 to 360] MME for buprenorphine and methadone patients, respectively. Preoperative buprenorphine was associated with a 59.9% lower postoperative MME (95% confidence interval: 46.6%-69.8%, P<0.0001) compared with methadone. Postoperative TWA pain scores for the first 48 hours were 5.0±2.7 (mean±SD), and 5.4±2.3 for buprenorphine and methadone patients, respectively. Preoperative buprenorphine was associated with a 0.37-point lower TWA pain score (95% confidence interval: 0.14-0.61, P=0.002) compared with methadone.
Preoperative buprenorphine use was associated with >50% reduction in postoperative opioid dose requirement and a statistically significant, though clinically unimportant, reduction in acute pain burden in comparison to methadone. The study is limited by several important factors such as the exclusion of patients requiring intravenous patient-controlled analgesia, small number of patients were on higher dose of buprenorphine, and a large percentage of methadone patients were not on a stable dose of methadone yet.
丁丙诺啡是μ-阿片受体的部分激动剂,在体外可与其他阿片类药物竞争这些受体。服用丁丙诺啡维持治疗的患者是否需要高剂量的阿片类镇痛药才能实现充分的术后疼痛控制尚未确定。我们评估了术前服用丁丙诺啡的患者与服用美沙酮的患者在术后急性阿片类药物消耗量和疼痛负担方面的差异。
对928例患者的病历进行回顾性研究,其中195例术前服用丁丙诺啡,733例术前服用美沙酮。在美沙酮和丁丙诺啡患者中,分别有615例和89例术后继续服用这些药物。将丁丙诺啡组患者与美沙酮组患者在术后的前48小时内,就急性阿片类药物剂量需求(高于其基线丁丙诺啡和美沙酮剂量的吗啡毫克当量[MME])和时间加权平均(TWA)疼痛评分(采用目标最大似然估计)进行比较。
术后48小时,丁丙诺啡组和美沙酮组患者的阿片类药物剂量需求分别为150(22至297)(中位数[四分位间距])和220[90至360]MME。与美沙酮相比,术前服用丁丙诺啡使术后MME降低了59.9%(95%置信区间:46.6%-69.8%,P<0.0001)。术后前48小时的TWA疼痛评分,丁丙诺啡组和美沙酮组分别为5.0±2.7(均值±标准差)和5.4±2.3。与美沙酮相比,术前服用丁丙诺啡使TWA疼痛评分降低了0.37分(95%置信区间:0.14-0.61,P=0.002)。
与美沙酮相比,术前使用丁丙诺啡可使术后阿片类药物剂量需求降低50%以上,且急性疼痛负担有统计学意义的降低,尽管在临床上并不重要。本研究受到几个重要因素的限制,如排除了需要静脉自控镇痛的患者、服用高剂量丁丙诺啡的患者数量较少,以及很大比例的美沙酮患者尚未服用稳定剂量的美沙酮。